Published On: 6/11/2024
EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at EASL 2024 titled “A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.”
Focusing on metabolic dysfunction-associated stereotactic liver disease (MASLD), the study investigated disease progression impact on patient-reported outcomes (PROs) and highlights the increased burden on patients as the disease advances. Watch this video presentation by Dr. Sanyal highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
12/11/2024
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD -
12/04/2024
The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR -
12/04/2024
ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR